Biofarm (BSE:BIO) Inventories, Work In Process: lei4.2 Mil (As of Mar. 2026)


BSE:BIO Biofarm SA BSE:BIO
69 GF Score
Price lei1.37
GF Value lei0.87
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Biofarm Inventories, Work In Process?

Biofarm BSE:BIO +0.37% 69 Inventories, Work In Process is lei4.2 Mil as of Mar. 2026. GuruFocus rates BSE:BIO with a GF Score™ of 69/100 and a GF Value™ of lei0.87 (Significantly Overvalued). The stock has 6 warning signs investors should review.

Work in process is the part of a manufacturer's inventory that is in the production process and has not yet been completed and transferred to the finished goods inventory. Biofarm's work in process for the quarter that ended in Mar. 2026 was lei4.2 Mil.

Biofarm Inventories, Work In Process Historical Data

* Premium members only.

The historical data trend for Biofarm's Inventories, Work In Process can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biofarm Inventories, Work In Process Chart

Biofarm Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Inventories, Work In Process
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.47 2.75 2.63 2.44 1.80

Biofarm Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Inventories, Work In Process Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.04 2.96 2.80 1.80 4.24
BSE:BIO
69GF Score
Biofarm SA BSE:BIO
Inventories, Work In Process is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Biofarm Inventories, Work In Process Calculation

That part of a manufacturer's inventory that is in the production process and has not yet been completed and transferred to the finished goods inventory. This account contains the cost of the direct material, direct labor, and factory overhead placed into the products on the factory floor. A manufacturer must disclose in its financial statements the cost of its work-in-process as well as the cost of finished goods and materials on hand.

What does a Inventories, Work In Process of lei4.2 Mil mean?
Biofarm (BSE:BIO) has a Inventories, Work In Process of lei4.2 Mil as of Mar. 2026. Work in progress is the portion of inventory containing goods that are unfinished. View historical data on Biofarm and its competitors.
Is Biofarm's Inventories, Work In Process too high?
Biofarm's current Inventories, Work In Process is lei4.2 Mil. Overall, Biofarm has a GF Score™ of 69/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Biofarm's Inventories, Work In Process compare to ZTS and UTHR?
Biofarm's Inventories, Work In Process of lei4.2 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Work In Process for a Drug Manufacturers company?
A good Inventories, Work In Process depends on the Drug Manufacturers industry context. However, Inventories, Work In Process should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Work In Process mean?
A high Inventories, Work In Process can signal that a stock is expensive relative to its fundamentals. Work in progress is the portion of inventory containing goods that are unfinished. View historical data on Biofarm and its competitors. Biofarm's current Inventories, Work In Process is lei4.2 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biofarm stock overvalued right now?
Based on GuruFocus' analysis, Biofarm (BSE:BIO) is currently considered Significantly Overvalued. The stock's GF Value™ is lei0.87, compared to a current price of lei1.37 — trading 57.5% above its estimated fair value. The current Inventories, Work In Process is lei4.2 Mil. Biofarm's overall GF Score™ is 69/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Work In Process calculated?
Inventories, Work In Process is calculated from a company's financial statements. For Biofarm (BSE:BIO), the current Inventories, Work In Process is lei4.2 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Biofarm (BSE:BIO) Overvalued in 2026?

Based on GuruFocus' analysis, Biofarm stock appears to be overvalued. The current stock price of lei1.37 is trading 57.5% above its estimated GF Value™ of lei0.87. GuruFocus considers Biofarm to be Significantly Overvalued.

Key valuation signals for BSE:BIO:

  • Inventories, Work In Process: lei4.2 Mil
  • GF Value™: lei0.87 vs. price of lei1.37 (57.5% above fair value)
  • GF Score™: 69/100 with 6 warning signs

No single metric tells the full story. See the BSE:BIO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Biofarm Business Description

Address 99 Logofatul Tautu Street, Sector 3, Bucharest, ROU, 031212
Biofarm SA is a company engaged in production and marketing in the pharmaceutical sector. It is involved in the manufacture and wholesale of over-the-counter drugs, prescription medications, and dietary supplements. The firm's product portfolio includes pharmaceutical preparations for the digestive system, musculoskeletal system, immune stimulation, respiratory system, cold & flu symptoms, and venous circulation improvement, as well as multivitamins, antioxidants, antiseptics, disinfectants, and cosmetics, among others. Some of its brands are Triferment, Colebil, Cavit, Anghirol, Clorocalcin, and Bixtonim. Additionally, the company offers services, such as investment in research, promotion, and packaging.
69GF Score

Get the complete analysis for BSE:BIO

Inventories, Work In Process is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

lei1.37
Price
lei0.87
GF Value